Aptinyx (APTX) Appoints Gilmore O’Neill to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- S&P 500, Nasdaq eye tepid open as Middle East tensions weigh
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Aptinyx Appoints Gilmore O’Neill, M.B., M.M.Sc., to Board of Directors
October 20, 2021 7:57 AM EDTEVANSTON, Ill.--(BUSINESS WIRE)-- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the appointment of Gilmore ONeill, M.B., M.M.Sc., to the companys board of directors. Dr. ONeill currently serves as chief medical officer and executive vice president of research and development at Sarepta Therapeutics.
Gilmore brings an exceptional background of experience and leadership to the Aptinyx board of directors, said Norbert Riedel, Ph.D., chief executive officer of Aptinyx. His expertise in research and clinical... More
